BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

Phase 2

Completed

Conditions: Various Advanced Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2015-03-13

Last Posted Date: 2022-11-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 270

Registration Number: NCT02387996

Locations: 🇺🇸
Local Institution - 0012, Duarte, California, United States
🇺🇸
Local Institution - 0052, Iowa City, Iowa, United States
🇺🇸
Crescent City Research Consortium, LLC, Marrero, Louisiana, United States

and more 61 locations

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Phase 3

Completed

Conditions: Lymphoma
Acute Lymphoblastic Leukemia

Interventions: Other: No systemic anticoagulant prophylaxis
Drug: Apixaban

First Posted Date: 2015-02-24

Last Posted Date: 2022-03-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 512

Registration Number: NCT02369653

Locations: 🇺🇸
Sinai Hospital Of Baltimore, Baltimore, Maryland, United States
🇺🇸
University Hospitals, Cleveland, Ohio, United States
🇺🇸
Children'S Center For Cancer And Blood Diseases, Indianapolis, Indiana, United States

and more 70 locations

Expanded Access Treatment Protocol CA204-143

Conditions: Multiple Myeloma

First Posted Date: 2015-02-23

Last Posted Date: 2023-11-30

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02368301

Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU)

Completed

Conditions: Hepatitis

First Posted Date: 2015-02-23

Last Posted Date: 2017-03-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 920

Registration Number: NCT02368522

Locations: 🇩🇪
Local Institution, Hamburg, Germany

Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population

Completed

Conditions: Chronic Myeloid Leukemia (CML)

First Posted Date: 2015-02-16

Last Posted Date: 2015-07-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 186

Registration Number: NCT02363868

Locations: 🇺🇸
Franklin Pharmaceutical Consulting, Llc, Clinton, South Carolina, United States

An Observational Study of the Functional Capacity of Heart Failure

Not Applicable

Completed

Conditions: Acute Heart Failure

Interventions: Procedure: 6 Minute Walk Test

First Posted Date: 2015-01-29

Last Posted Date: 2016-07-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 51

Registration Number: NCT02350114

Locations: 🇺🇸
Cardioxyl Study Site, Nashville, Tennessee, United States

Factors Associated With Biologic DMARD Switching

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2015-01-27

Last Posted Date: 2016-02-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 4099

Registration Number: NCT02346942

Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico

Completed

Conditions: Pulmonary Embolism
Deep Vein Thrombosis

Interventions: Drug: Apixaban

First Posted Date: 2015-01-26

Last Posted Date: 2017-06-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT02345343

Locations: 🇲🇽
Local Institution, Queretaro, Mexico

A Study of BMS-986148 in Patients With Select Advanced Solid Tumors

Phase 1

Terminated

Conditions: Advanced Cancer

Interventions: Drug: BMS-986148
Biological: Nivolumab

First Posted Date: 2015-01-19

Last Posted Date: 2022-08-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 126

Registration Number: NCT02341625

Locations: 🇦🇺
Local Institution - 0013, Liverpool, New South Wales, Australia
🇦🇺
Local Institution - 0014, Adelaide, South Australia, Australia
🇧🇪
Local Institution - 0008, Gent, Oost-Vlaanderen, Belgium

and more 14 locations

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: BMS-986141
Drug: Placebo
Drug: Aspirin
Drug: Itraconazole

First Posted Date: 2015-01-19

Last Posted Date: 2017-03-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 148

Registration Number: NCT02341638

Locations: 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States
🇺🇸
Ppd Development, Lp, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy